Partner
Emily Gabranski focuses on complex patent and trade secret litigation, primarily in the biotechnology, biologics, and pharmaceutical fields. She represents clients in U.S. district courts, where she has served as trial counsel in bench trials for Hatch-Waxman cases and in jury trials for brand-on-brand litigation.
Emily has significant experience in all phases of pre-litigation and litigation, as well as counseling and diligence matters, pertaining to a wide range of technologies, including small molecule pharmaceuticals, therapeutic antibodies, inorganic chemistry, semiconductors, and gene therapies. She was named on the Best Lawyers “Ones to Watch” list in 2023-2025.
Prior to joining Finnegan, Emily conducted research in cellular and molecular neurobiology. Her research focused on transmitter modulation of neuronal network interactions. She coauthored two peer-reviewed publications in scientific journals and presented her research at a Society for Neuroscience annual meeting.
Emily is devoted to pro bono work and has successfully represented clients in custody disputes, post-conviction relief under the Incarceration Reduction Amendment Act (IRAA), and in asylum proceedings. She has been recognized on the Capital Pro Bono Honor Roll.
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.
Represented Novartis against Genzyme related to recombinant adeno-associated virus vector technology used in Novartis’ blockbuster, breakthrough gene therapy Zolgensma®. The case settled after four patents were invalidated during claim construction, five patents found not literally infringed, and institution of multiple inter partes reviews (IPRs).
1:21-cv-01736, 1:23-cv-00554, D. Del., Judge Andrews
American Regent, Inc. v. Pharmacosmos Therapeutics Inc. et al.
Counsel for American Regent in litigation in the District of New Jersey against Pharmacosmos and their branded drug, Monoferric®, related to American Regent patents covering the use of iron carbohydrate complexes for the treatment of iron deficiency diseases. The case resulted in a favorable settlement for our client.
PGR2020-00009, PTAB, Judges Tornquist, Franklin, Wisz
3:20-cv-01350, D.N.J., Judges Goodman, Martinotti, Quraishi
Eli Lilly and Company v. Teva Pharmaceuticals International
Member of a team that represented Eli Lilly in multiple inter partes review (IPR) proceedings involving antibody therapies.
IPR2018-01422; -01423; -01424; -01425; -01426; -01427; -01710, -01711, -01712, PTAB
Duchesnay, Inc. v. Actavis Laboratories Inc. and Mylan Pharmaceuticals, Inc.
1:14-cv-00912, D. Del., Judges Robinson, Fallon
CMC Materials, LLC v. Dupont de Nemours, Inc. et al.
1:20-cv-00738, D. Del., Judge Hall
Vifor (International) AG and American Regent, Inc. v. Mylan Labs. Ltd. et al.
3:19-cv-13955, 3:19-cv-16305, D.N.J., Judges Wolfson, Arpert
Articles
D. Mass. Patent Litigation Update: December 2024 D. Mass. Patent Litigation Update: December 2024
January 29, 2025
Articles
Using Contracts As Evidence Of Trade Secret Protection Using Contracts As Evidence Of Trade Secret Protection
December 18, 2024
Law360Articles
D. Mass. Patent Litigation Update: September 2024 D. Mass. Patent Litigation Update: September 2024
October 31, 2024
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Articles
D. Mass. Patent Litigation Update: March 2024 D. Mass. Patent Litigation Update: March 2024
April 26, 2024
Articles
D. Mass. Patent Litigation Update: February 2024 D. Mass. Patent Litigation Update: February 2024
April 1, 2024
Award/Ranking
Best Lawyers Recognizes 44 Finnegan Attorneys in its 2026 Edition of The Best Lawyers and Ones to Watch Best Lawyers Recognizes 44 Finnegan Attorneys in its 2026 Edition of The Best Lawyers and Ones to Watch
August 21, 2025
Best LawyersPress Release
Twelve Attorneys Elevated to Finnegan Partnership Twelve Attorneys Elevated to Finnegan Partnership
January 7, 2025
Award/Ranking
31 Finnegan Attorneys Recognized by Best Lawyers 31 Finnegan Attorneys Recognized by Best Lawyers
August 15, 2024
Best LawyersAward/Ranking
60 Finnegan Attorneys Named to 2023 Capital Pro Bono Honor Roll 60 Finnegan Attorneys Named to 2023 Capital Pro Bono Honor Roll
May 15, 2024
Press Release
32 Finnegan Attorneys Recognized by Best Lawyers 32 Finnegan Attorneys Recognized by Best Lawyers
August 17, 2023
Best LawyersDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.